Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Botulism A-E monoclonal antibody
- Development stage
- Preclinical
- Lead developer
- Mapp Biopharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intramuscular, Intravenous
01
Overview
Botulism A-E monoclonal antibody is an experimental anti-toxin therapeutic being developed by Mapp Biopharmaceutical and its commercial arm, LeafBio. The drug is designed as a cocktail of monoclonal antibodies intended for both the prophylaxis and treatment of botulism caused by Clostridium botulinum neurotoxin (BoNT) serotypes A, B, C, D, and E. Its mechanism of action involves the high-affinity binding and neutralization of these neurotoxins in the systemic circulation, thereby preventing the toxins from interacting with neuronal receptors and entering nerve terminals. By blocking toxin entry, the antibody cocktail prevents the cleavage of SNARE proteins and the subsequent inhibition of acetylcholine release, which otherwise leads to the characteristic flaccid paralysis of botulism. The program is currently in the IND-enabling stage of development.
- Other names
- Botulism (serotypes A–E) — prophylaxis/therapy
02
Targets
BoNT/B (Botulinum neurotoxin type B)BoNT/E (Botulinum neurotoxin type E)BoNT/A (Botulinum neurotoxin type A)
Beyond the preview
Go deeper on Botulism A-E monoclonal antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Botulism A-E monoclonal antibody.